

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

**LOAN FACILITY WITH BANK OF CHINA (HONG KONG) -
ANNOUNCEMENT PURSUANT TO RULE 13.18 OF THE LISTING RULES**

The Company, as borrower, has entered into the Revised Facility Letter with Bank of China (Hong Kong) Limited for term loan facilities up of HKD400,000,000.

The Facility Letter imposes, among other matters, specific performance obligations on the controlling shareholders of the Company.

This announcement is made pursuant to Rule 13.18 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”).

Reference is made to the announcement of the Company dated 13 September 2021 (the “Announcement”). Unless otherwise defined, all capital terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Board announces that the Company, as borrower, has entered into a revised facility letter (the “Revised Facility Letter”) with Bank of China (Hong Kong) Limited for term loan facilities of (i) term loan of HKD200,000,000 (“Term Loan 1”), being the original term loan under the Facility Letter; and (ii) term loan up to HKD200,000,000 or its equivalent amount in USD (“Term Loan 2”). The term loan facility shall be available for drawdown within 3 months from the acceptance of the Revised Facility Letter. The Term Loan 1 shall be repaid in full one year from the date of first drawdown. The Term Loan 2 shall be repaid by four instalments as 10%, 20%, 20% and 50% of the total outstanding balance as at the end of the term loan facility available period in the 18, 24, 30 and 36 months respectively from the date of first drawdown.

The Revised Facility Letter imposes, among other matters, Mr. Tsoi Hoi Shan and his family members shall (i) maintain as the chairman of the Board; (ii) remain as the single largest shareholder of the Company and maintain not less than 40% shareholdings of the Company (whether directly or indirectly); and (iii) remain the absolute management control of the Company and its group.

The Company will continue to comply with the disclosure obligations under Rule 13.21 of the Listing Rules for so long as circumstance giving rise to the above obligation continue to exist.

On behalf of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 30 May 2022

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.